CancerAppy
Novel cancer therapeutic drugs
At CancerAppy, we specialize in cancer research, dedicated to discovering and developing new therapeutic targets. Our proprietary artificial intelligence methodology allows us to accelerate advancements in more effective cancer treatments
Driving innovation in breakthrough oncology treatments.
With our deep expertise in oncology and AI, we analyze vast amounts of multimodal data using advanced AI algorithms. This allows us to identify new therapeutic targets, discover lead compounds, understand their mechanisms of action, and explore potential drug combinations. Our technology also enables the development of next-generation antibody-drug conjugates (ADCs), driving more precise and effective cancer treatments.

We work in the early stage of the Drug Discovery Value Chain.

Our R&D Pipeline
At CancerAppy, we use AI-driven drug discovery to develop new cancer therapies, including novel ADCs (antibody-drug conjugates). Our pipeline moves from target discovery to preclinical development, bringing innovative treatments closer to patients.
News
Latest news about CancerAppy…
Icex Next
CancerAppy SL en el marco del Programa ICEX Next, ha contado con el apoyo de ICEX y con la cofinanciación del fondo europeo FEDER. La...
B-Venture 2021
We once again attend the B-venture 2021 event in Bilbao this time under the sponsorship of DeustoEmprende.
11 Most Innovative Pais Vasco Based Artificial Intelligence Companies
Cancerappy has been selected as one of the 11 most innovative companies in artificial intelligence in the Basque Country. More info...
Grant CPP2021-008597 funded by:

Grant TQ2020-011486 funded by:


Subvencionado por el CDTI

Somos cliente Enisa

